Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
- 1 May 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 97 (9) , 2886-2895
- https://doi.org/10.1182/blood.v97.9.2886
Abstract
In allogeneic bone marrow transplantation (BMT) donor T cells are primarily responsible for antihost activity, resulting in graft-versus-host disease (GVHD), and for antileukemia activity, resulting in the graft-versus-leukemia (GVL) effect. The relative contributions of the Fas ligand (FasL) and perforin cytotoxic pathways in GVHD and GVL activity were studied by using FasL-defective or perforin-deficient donor T cells in murine parent --> F1 models for allogeneic bone marrow transplantation. It was found that FasL-defective B6.gld donor T cells display diminished GVHD activity but have intact GVL activity. In contrast, perforin-deficient B6.pfp(-/-) donor T cells have intact GVHD activity but display diminished GVL activity. Splenic T cells from recipients of B6.gld or B6.pfp(-/-) T cells had identical proliferative and cytokine responses to host antigens; however, splenic T cells from recipients of B6.pfp(-/-) T cells had no cytolytic activity against leukemia cells in a cytotoxicity assay. In experiments with selected CD4(+) or CD8(+) donor T cells, the FasL pathway was important for GVHD activity by both CD4(+) and CD8(+) T cells, whereas the perforin pathway was required for CD8-mediated GVL activity. These data demonstrate in a murine model for allogeneic bone marrow transplantation that donor T cells mediate GVHD activity primarily through the FasL effector pathway and GVL activity through the perforin pathway. This suggests that donor T cells make differential use of cytolytic pathways and that the specific blockade of one cytotoxic pathway may be used to prevent GVHD without interfering with GVL activity.Keywords
This publication has 55 references indexed in Scilit:
- Perforin Gene Defects in Familial Hemophagocytic LymphohistiocytosisScience, 1999
- Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor α and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophyGut, 1999
- Apoptosis by Death FactorCell, 1997
- Molecular Mechanisms of Lymphocyte-Mediated Cytotoxicity and Their Role in Immunological Protection and Pathogenesis In VivoAnnual Review of Immunology, 1996
- Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated CytotoxicityScience, 1994
- Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient miceNature, 1994
- Generation of Donor-Derived Antileukemic Cytotoxic T-Lymphocyte Responses for Treatment of Relapsed Leukemia After Allogeneic HLA-Identical Bone Marrow TransplantationJournal of Immunotherapy, 1993
- Metabolic inhibitors distinguish cytolytic activity of CD4 and CD8 clonesEuropean Journal of Immunology, 1990
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987
- Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivityNature, 1979